Convergence: CBER chief discusses priorities, touts gene therapy approvals

Regulatory News

Regulatory NewsJoanne S. Eglovitch

Biologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States